Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Prolacta Bioscience
AddedFeb 15, 2024
UpdatedJun 18, 2026
Prolacta Bioscience

Prolacta Bioscience

Series A

Prolacta Bioscience develops specialty human milk formulations for premature and ill infants' nutrition.

HQ
City of Industry, CA, US
Founded
1999
Overview
Compare
Fundraising
Employees
Website

Prolacta Bioscience, founded with the mission to transform care for vulnerable infants, focuses on developing specialty formulations made from human milk. The company provides human milk-based nutritional products specifically designed to meet the needs of premature and critically ill infants in neonatal intensive care units (NICUs). By leveraging the biological power of human milk, Prolacta aims to improve health outcomes and reduce complications for these infants, operating primarily within the United States.

Notable figures affiliated with Prolacta Bioscience include its team of leading scientists and healthcare professionals dedicated to neonatal nutrition. The company has garnered significant investment from healthcare-focused venture capital firms. Key achievements include multiple clinical studies published in peer-reviewed journals that validate the efficacy of their products in improving infant health outcomes. Prolacta's impact is profound, as its human milk-based nutritional products have become a critical component in the care regimen for premature infants, contributing to better survival rates and reduced hospital stays.

Prolacta Bioscience - Quick Facts

When was Prolacta Bioscience founded?

Prolacta Bioscience was founded in 1999.

Where is Prolacta Bioscience's headquarters located?

Prolacta Bioscience's headquarters is located in City of Industry, CA, US.

When was Prolacta Bioscience's last funding round?

Prolacta Bioscience's most recent funding round was for $8.9M (USD) in May 2018.

How much has Prolacta Bioscience raised to-date?

As of May 15, 2018, Prolacta Bioscience has raised a total of $78M (USD).

How many employees does Prolacta Bioscience have?

Prolacta Bioscience has 347 employees as of Feb 5, 2024.

Prolacta Bioscience - Classification

Ownership
  • Private
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Formulations
  • Human Milk
Tags
  • Distribution
  • Healthcare
  • Healthtech
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 2830Drugs
  • 2834Pharmaceutical Preparations